HemOnc Today New York

Healio.com brings you the highlights from HemOnc Today New York. Refer back to this page often to read the latest news, see perspectives and interviews with leading researchers and clinicians, and review archives of past meetings.
Meeting News

BRAF genotypes exhibit different clinical, pathologic profiles

March 28, 2017
NEW YORK — An analysis of the clinical and pathologic profiles of BRAF genotypes among individuals with melanoma revealed differences related…
Meeting NewsVideo

VIDEO: Intralesional agent, immunotherapy combination may increase response in metastatic melanoma

March 27, 2017
NEW YORK — Robert H.I. Andtbacka, MD, CM, FACS, FRCSC, surgical oncologist at Huntsman Cancer Institute, and a HemOnc Today Editorial…
Meeting News

Nivolumab, pembrolizumab exhibit different toxicity profiles as melanoma monotherapy

March 27, 2017
NEW YORK — Nivolumab and pembrolizumab exhibited different toxicity profiles and appeared associated with different adverse event frequencies…
Meeting NewsVideo

VIDEO: Highlights from the 2017 HemOnc Today Melanoma and Cutaneous Malignancies meeting

March 26, 2017
NEW YORK — Sanjiv S. Agarwala, MD, professor of medicine at Temple University School of Medicine, chief of hematology and oncology at St…
Meeting NewsVideo

VIDEO: New immune targets may improve advanced melanoma outcomes

March 25, 2017
NEW YORK — Michael A. Postow, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discussed new immunotherapy targets for…
Meeting News

Anti–PD-1/PD-L1 therapy ‘rapidly becoming’ standard of care for Merkel cell carcinoma

March 25, 2017
NEW YORK — Immunosuppressive therapies, including anti–PD-1/PD-L1 agents, have led to durable responses among patients with Merkel cell…
Meeting News

Challenges remain in determining appropriate sequence of immunotherapy, BRAF/MEK inhibition

March 25, 2017
NEW YORK — The optimal sequence of immunotherapy and BRAF/MEK inhibition for the first-line treatment of melanoma has only been evaluated…
Meeting News

Hedgehog inhibitors ‘game changers’ for advanced basal cell carcinoma

March 25, 2017
NEW YORK — Hedgehog inhibitors have demonstrated high efficacy and durability for patients with advanced basal cell carcinoma, according to a…
Meeting News

Baseline factors predict survival benefit from BRAF/MEK inhibitor combination

March 25, 2017
Baseline lactic acid dehydrogenase levels, the sum of target lesion diameters and the number of organ sites with metastases predicted survival…
Meeting News

Molecular testing requires additional validation before ready for prime time in melanoma

March 25, 2017
NEW YORK — Preliminary and validation studies have been conducted on molecular testing methods for melanoma prognostication, but these methods…